Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
WPD Pharmaceuticals Inc
WPDPF
Primary Symbol:
C.WBIO
Industrials
Technology
WPD Pharmaceuticals Inc. is a Canada-based clinical-stage pharmaceutical company, with a focus on glioblastoma cancer (GBM) and other brain tumor programs. The Company is a biotechnology research and development company with a focus on oncology, namely research and development of medicinal products involving biological compounds and small molecules. It has four novel drug candidates with one in...
clinical development stage and three in pre-clinical development. It operates its business primarily through WPD Poland, a subsidiary of and the operating branch of the Company. Its portfolio includes WPD101, Berubicin, and WPD103. WPD101 is a family of biopharmaceuticals in preclinical stages of development for targeted treatment of brain tumors with a global license. Berubicin is an anthracycline proven to cross the blood-brain barrier and able to reach brain tumors.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (CSE:WBIO)
New Post
View:
Posts & Comments
Threaded Posts
Prev
1
2
3
Next
(3216)
•••
Betteryear2
X
View Profile
View Bullboard History
Post by
Betteryear2
on Mar 07, 2022 7:57am
Signs Consortium Agreement on EuroNanoMed Project
VANCOUVER, British Columbia, March 07, 2022 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (CSE: WBIO)(FSE: 8SV1) (the “Company” or “WPD”) a clinical-stage pharmaceutical
...more
(10)
•••
Blocky
X
View Profile
View Bullboard History
Post by
Blocky
on Jan 10, 2021 10:50am
WPD and Moleculin could...
WPD and Moleculin could be worth over 300 million? Only because of one drug? https://ir.moleculin.com/press-releases/detail/201/moleculin-announces-fda-approves-3-rare-pediatric-disease
...more
QMET has 11 claims and 633 hectares Property in Ville-Marie, Quebec Hydrogen Camp
posted Nov 25, 2024 9:00am by
Q Precious & Battery Metals Corp.
-
|
The Company is pleased to discover that their Lorrain claims are now within the new and exciting exploration for hydrogen in the Ville-Marie, Lorrainville and Béarn region of Quebec. The region has undergone a claim staking rush following the ...read more
(10)
•••
Blocky
X
View Profile
View Bullboard History
Comment by
Blocky
on Jan 08, 2021 9:50am
RE:Ph.D. Waldemar Priebe = new Jeff Bezos
If the CEO of WPD is the new Jeff Bezos, then we will be rich very soon...
(10)
•••
Blocky
X
View Profile
View Bullboard History
Comment by
Blocky
on Jan 08, 2021 9:30am
RE:WPD Berubicin Drug Candidate trial to start
Good Guy! New Blockbuster in the market?
(10)
•••
Blocky
X
View Profile
View Bullboard History
Comment by
Blocky
on Jan 08, 2021 7:00am
RE:WPD Berubicin Drug Candidate trial to start
When will we get the first results?
(10)
•••
Blocky
X
View Profile
View Bullboard History
Post by
Blocky
on Jan 08, 2021 6:52am
Ph.D. Waldemar Priebe = new Jeff Bezos
Waldemar Priebe is my new Jeff Bezos! Mr. Priebe is the founder of WPD Pharmaceuticals, the founder of Reta Pharmaceuticals (whose stock has risen from $11 to $260), the founder of CNS
...more
(10)
•••
Blocky
X
View Profile
View Bullboard History
Post by
Blocky
on Jan 07, 2021 4:36pm
Berubicin + Covid19 drug: let´s get ready to rumble!
Not only Berubicin cound be worth more than 1 billion, but also WP1122 could heal Covid19 patients... let´s get ready to rumble!
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Oct 26, 2020 8:10am
WPD Berubicin Drug Candidate trial to start
Last week, WPD met with Worldwide Clinical Trials, a world-renowned Contract Research Organization engaged to coordinate and supervise the start-up of WPD’s Phase 1 and 2 clinical trials on Berubicin.
...more
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Oct 15, 2020 8:06am
New Chief Medical Officer to Lead Phase I and II Clinic Tria
Marek has over 20 years of experience in clinical research in oncology (haematology and solid tumours), neuropsychiatry, diabetes and cardiovascular fields. He brings international expert knowledge
...more
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Sep 17, 2020 8:20am
US FDA Grant Fast-Track Glioblastoma Treatments
Unfortunately, glioblastoma is an aggressive brain tumor that still remains difficult to treat. To this day, there is still an unmet need for treatment, with only 8.7% of patients surviving for up to
...more
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Sep 16, 2020 7:48am
Prepayment of $705,000
WPD Pharmaceuticals Receives Second Prepayment of $705,000 from Total $7.4 Million Grant for Development of WPD101 VANCOUVER, British Columbia, Sept. 16, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals
...more
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Sep 09, 2020 7:51am
Worldwide Clinical Trials as CRO for Phase 2 Berubicin Trial
VANCOUVER, British Columbia, Sept. 09, 2020 (GLOBE NEWSWIRE) -- WPD Pharmaceuticals Inc. (“WPD” or the “Company”) (CSE: WBIO) (FSE: 8SV1), a clinical stage pharmaceutical company, is pleased to
...more
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Sep 01, 2020 9:42am
WPD Demonstrating Highly Effective Anticancer Therapy
WPD Pharmaceuticals Announces New Publication Demonstrating Highly Effective Anticancer Therapy in Animals with Spontaneous Tumors using WPD101 Drug Candidate Combination of IL-13RA2- and EphA2
...more
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Jul 28, 2020 7:54am
Killer of malignant tumors of the central nervous system
The breakthrough of WPD’s solution is that WPD101a binds specifically to IL-13α2 receptors overexpressed on GBM cells. Binding of WPD101a to IL-13Rα2 expressing tumor cells is followed by
...more
(16)
•••
etcetera
X
View Profile
View Bullboard History
Post by
etcetera
on Jul 23, 2020 7:53am
Testing Confirms Antiviral Activity
Second round of independent laboratory testing confirmed the antiviral activity of WP1122 against coronavirus WP1122 against coronavirus July 23, 2020 07:30 ET | Source: WPD
...more
Prev
1
2
3
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
One Property, One Focus on Advancing this Gold Project in Ontario
Options Trading for Retiring: Key Strategies in Balancing Retirement Income